Chandra Asri, Medco, Tabungan Negara: Indonesian Equity Preview

Shares of the following companies may have unusual moves in Indonesian trading. Stock symbols are in parentheses, and share prices are as of the previous close.

The Jakarta Composite index (JCI) rose 2.4 percent to 3,706.78.

Energy companies: Crude oil for December delivery rose to a two-month high, adding 4.4 percent to $91.27 a barrel in New York yesterday. The contract was at $91.37 a barrel in after- hours trading.

PT Medco Energi Internasional (MEDC IJ), Indonesia’s biggest listed oil company, climbed 2.4 percent to 2,150 rupiah. PT Energi Mega Persada (ENRG IJ), the second largest, rose 0.6 percent to 166 rupiah.

PT Bank Central Asia (BBCA IJ): The company’s net income in the nine months to September rose 25 percent to 7.7 trillion rupiah ($869 million) from a year earlier, Indonesia’s biggest bank by market value said. Bank Central Asia increased 3.9 percent to 7,950 rupiah.

PT Bank Tabungan Negara (BBTN IJ): The company’s net income in the nine months to September rose to 707.4 billion rupiah from 678 billion rupiah a year earlier, the state-owned mortgage lender said in a statement published in Bisnis Indonesia. Bank Tabungan gained 3.5 percent to 1,490 rupiah.

PT Chandra Asri Petrochemical (TPIA IJ): The petrochemical producer is seeking a bank loan of $150 million to $250 million to fund the completion of a plant, Bisnis Indonesia reported, citing Investor Relations Director Suryandi. Chandra Asri jumped 7.7 percent to 3,150 rupiah.

PT Kimia Farma (KAEF IJ): The pharmaceutical company plans to raise 901.9 billion rupiah selling new shares in the second quarter next year, Investor Daily Indonesia reported, citing President Director Muhammad Sjamsul Arifin. The funds will be used to develop its pharmacy business and set up a joint venture, the newspaper said. Kimia Farma gained 4 percent to 260 rupiah.

To contact the reporter on this story: Berni Moestafa in Jakarta at bmoestafa@bloomberg.net

To contact the editor responsible for this story: Darren Boey at dboey@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.